Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst

By: TheNewswire.com
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ: TLSA). Tiziana has disclosed plans to file INDs (Investigational New Drug applications) aiming to expand the clinical indications of its lead product, intranasal foralumab, into mild-to-moderate Alzheimer’s Disease (AD) and long COVID-19.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  273.55
+1.50 (0.55%)
AAPL  284.18
+7.35 (2.66%)
AMD  355.26
+13.72 (4.02%)
BAC  53.12
+0.93 (1.78%)
GOOG  384.27
+4.63 (1.22%)
META  604.96
-5.45 (-0.89%)
MSFT  411.38
-2.24 (-0.54%)
NVDA  196.50
-1.98 (-1.00%)
ORCL  185.35
+5.06 (2.81%)
TSLA  389.37
-3.14 (-0.80%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.